The DNASE2 knockout HeLa polyclonal cells are a CRISPR/Cas9-mediated gene disruption product designed to abolish expression of the DNASE2 gene, yielding a polyclonal knockout population. This loss-of-function model is generated by targeted disruption of DNASE2, the gene encoding a lysosomal endonuclease integral to DNA degradation and innate immune regulation. The polyclonal nature ensures representation of diverse editing outcomes, making it suitable for functional studies where clonal heterogeneity is acceptable and bulk cellular responses are prioritized.
The host HeLa cell line is a human cervical adenocarcinoma cell line derived from cervical cancer tissue, widely employed in cancer biology and biomedical research. HeLa cells are HPV-18 positive, leading to the expression of viral oncoproteins E6 and E7 that inactivate the tumor suppressors p53 and Rb. This immortalized epithelial background provides a robust platform for investigating mechanisms of oncogenesis, apoptosis, and host?Cpathogen interactions, particularly in the context of viral-mediated immune evasion.
DNASE2 functions as an acid-optimal endonuclease within lysosomes, where it degrades DNA from apoptotic bodies and foreign sources. Its activity is regulated by upstream signals including TP53, TFEB, MITF, and metabolic or genotoxic stress. The enzyme interacts with lysosomal constituents such as LAMP1, LAMP2, and cathepsins, as well as the serpin SERPINB9. Disruption of DNASE2 results in accumulation of undegraded DNA fragments, which leak into the cytosol or endosomal compartments. These ligands activate pattern recognition receptors including endosomal TLR9 and the cGAS-STING pathway, engaging adaptors MyD88 and STING to drive NF-??B and IRF3 signaling, culminating in type I interferon (e.g., IFN-??) and pro-inflammatory cytokine production.
In the HeLa cell context, where p53 and Rb are functionally absent due to HPV-18 oncoproteins, DNASE2 knockout may accentuate DNA-driven innate immune activation, providing a model to explore intersections between lysosomal dysfunction and viral oncogenesis. This system allows dissection of how loss of lysosomal DNA clearance synergizes with impaired tumor suppressor pathways to modulate cell death, senescence, and inflammatory signaling, with implications for both cancer progression and autoimmune phenomena.
The DNASE2 knockout HeLa polyclonal cells support a spectrum of research applications, including mechanistic studies of lysosomal DNA degradation, innate immunity, and inflammation. Investigators can employ assays such as DNase activity measurements, immunoblotting, immunofluorescence for lysosomal DNA accumulation, RT-qPCR for IFN-?? and cytokine transcripts, ELISA for secreted factors, and flow cytometry for cell death or cGAS-STING pathway activation. This model is also valuable for therapeutic target evaluation in autoimmune and inflammatory diseases. For further technical details or assistance, please contact Ascent Research.
